{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T09:09:54Z","timestamp":1792400994920,"version":"4.4.0"},"reference-count":89,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T00:00:00Z","timestamp":1706227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Diabetes mellitus is a devastating chronic metabolic disease. Since the majority of type 2 diabetes mellitus patients are overweight or obese, a novel term\u2014diabesity\u2014has emerged. The gut\u2013brain axis plays a critical function in maintaining glucose and energy homeostasis and involves a variety of peptides. Amylin is a neuroendocrine anorexigenic polypeptide hormone, which is co-secreted with insulin from \u03b2-cells of the pancreas in response to food consumption. Aside from its effect on glucose homeostasis, amylin inhibits homeostatic and hedonic feeding, induces satiety, and decreases body weight. In this narrative review, we summarized the current evidence and ongoing studies on the mechanism of action, clinical pharmacology, and applications of amylin and its analogs, pramlintide and cagrilintide, in the field of diabetology, endocrinology, and metabolism disorders, such as obesity.<\/jats:p>","DOI":"10.3390\/ijms25031517","type":"journal-article","created":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T04:05:46Z","timestamp":1706241946000},"page":"1517","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Amylin, Another Important Neuroendocrine Hormone for the Treatment of Diabesity"],"prefix":"10.3390","volume":"25","author":[{"given":"Stjepan","family":"Er\u017een","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8268-1695","authenticated-orcid":false,"given":"Ga\u0161per","family":"Tonin","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia"},{"name":"Faculty of Arts, University of Ljubljana, 1000 Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dubravka","family":"Juri\u0161i\u0107 Er\u017een","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetology, University Hospital Centre, 51000 Rijeka, Croatia"},{"name":"Department of Internal Medicine, Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasna","family":"Klen","sequence":"additional","affiliation":[{"name":"Division of Surgery, Department of Abdominal Surgery, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia"},{"name":"Department of Internal Medicine, Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","article-title":"Global, Regional, and National Burden of Diabetes from 1990 to 2021, with Projections of Prevalence to 2050: A Systematic Analysis for the Global Burden of Disease Study 2021","volume":"402","author":"Ong","year":"2023","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1161521","DOI":"10.3389\/fendo.2023.1161521","article-title":"Obesity and Type 2 Diabetes Mellitus: Connections in Epidemiology, Pathogenesis, and Treatments","volume":"14","author":"Ruze","year":"2023","journal-title":"Front. Endocrinol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJMoa021778","article-title":"Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 Diabetes","volume":"348","author":"Vedel","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, K.B., Ostolaza, H., and Mart\u00edn, C. (2020). Pathophysiology of Type 2 Diabetes Mellitus. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21176275"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"R38","DOI":"10.1530\/EC-17-0347","article-title":"On Type 1 Diabetes Mellitus Pathogenesis","volume":"7","author":"Paschou","year":"2018","journal-title":"Endocr. Connect."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"396","DOI":"10.4239\/wjd.v14.i4.396","article-title":"Management of Diabesity: Current Concepts","volume":"14","author":"Michaelidou","year":"2023","journal-title":"World J. Diabetes"},{"key":"ref_7","first-page":"457","article-title":"Endocrine and Metabolic Effects of Experimental Obesity in Man","volume":"29","author":"Sims","year":"1973","journal-title":"Recent. Prog. Horm. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2337\/cd17-0083","article-title":"Personalizing Type 2 Diabetes Management: Use of a Patient-Centered Approach to Individualizing A1C Goals and Pharmacological Regimens","volume":"35","author":"Lahiri","year":"2017","journal-title":"Clin. Diabetes"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/s41575-023-00830-y","article-title":"The Intestine as an Endocrine Organ and the Role of Gut Hormones in Metabolic Regulation","volume":"20","author":"Reimann","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/s41574-019-0168-8","article-title":"Function and Mechanisms of Enteroendocrine Cells and Gut Hormones in Metabolism","volume":"15","author":"Gribble","year":"2019","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1002\/(SICI)1096-9136(199706)14:2+<S9::AID-DIA397>3.0.CO;2-D","article-title":"Amylin: History and Overview","volume":"14","author":"Ludvik","year":"1997","journal-title":"Diabet. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0165-6147(93)90081-T","article-title":"Structure and Biology of Amylin","volume":"14","author":"Rink","year":"1993","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1111\/bph.13496","article-title":"Amylin Structure\u2013Function Relationships and Receptor Pharmacology: Implications for Amylin Mimetic Drug Development","volume":"173","author":"Bower","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"ref_14","unstructured":"(2023, December 28). PubChem Amylin (1\u201313) (Human), Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/102601526."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Cao, J., Belousoff, M., Gerrard, E., Danev, R., Fletcher, M., Maso, E., Schreuder, H., Lorenz, K., Evers, A., and Tiwari, G. (2023). Structural Insight into Selectivity of Amylin and Calcitonin Receptor Agonists. Nat. Chem. Biol., 1\u20138.","DOI":"10.1038\/s41589-023-01393-4"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Lima, L.M.T.R., and Icart, L.P. (2022). Amyloidogenicity of Peptides Targeting Diabetes and Obesity. Colloids Surf. B Biointerfaces, 209.","DOI":"10.1016\/j.colsurfb.2021.112157"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jinorgbio.2018.11.004","article-title":"Interaction of Amylin Species with Transition Metals and Membranes","volume":"191","author":"Alghrably","year":"2019","journal-title":"J. Inorg. Biochem."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Yang, F. (2014). Amylin in Vasodilation, Energy Expenditure and Inflammation. Front. Biosci., 19.","DOI":"10.2741\/4258"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Boyle, C.N., Zheng, Y., and Lutz, T.A. (2022). Mediators of Amylin Action in Metabolic Control. J. Clin. Med., 11.","DOI":"10.3390\/jcm11082207"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"105965","DOI":"10.1016\/j.appet.2022.105965","article-title":"Creating the Amylin Story","volume":"172","author":"Lutz","year":"2022","journal-title":"Appetite"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Lutz, T. (2022, January 14\u201316). Therapeutic Potential of an Old Friend\u2014The Dichotomy of Amylin in Physiology and Pathophysiology. Proceedings of the Endocrine Abstracts, Harrogate, UK.","DOI":"10.1530\/endoabs.86.S2.1"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJM200008103430607","article-title":"Islet Amyloid and Type 2 Diabetes Mellitus","volume":"343","author":"Lips","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jcb.240550004","article-title":"Molecular Physiology of Amylin","volume":"55","author":"Pittner","year":"1994","journal-title":"J. Cell. Biochem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1124\/pr.115.010629","article-title":"Amylin: Pharmacology, Physiology, and Clinical Potential","volume":"67","author":"Hay","year":"2015","journal-title":"Pharmacol. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1055\/s-0029-1211958","article-title":"The Role of Amylin in the Physiology of Glycemic Control","volume":"106","author":"Scherbaum","year":"2009","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0026-0495(97)90170-0","article-title":"Dose-Response for Glucagonostatic Effect of Amylin in Rats","volume":"46","author":"Gedulin","year":"1997","journal-title":"Metabolism"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3389\/fnins.2015.00216","article-title":"Amylin at the Interface between Metabolic and Neurodegenerative Disorders","volume":"9","author":"Lutz","year":"2015","journal-title":"Front. Neurosci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3389\/fendo.2017.00324","article-title":"Involvement of Amylin and Leptin in the Development of Projections from the Area Postrema to the Nucleus of the Solitary Tract","volume":"8","author":"Abegg","year":"2017","journal-title":"Front. Endocrinol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"R1395","DOI":"10.1152\/ajpregu.00597.2001","article-title":"Effects of Amylin-Related Peptides on Food Intake, Meal Patterns, and Gastric Emptying in Rats","volume":"282","author":"Reidelberger","year":"2002","journal-title":"Am. J. Physiol.-Regul. Integr. Comp. Physiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.physbeh.2004.01.006","article-title":"Infusion of the Amylin Antagonist AC 187 into the Area Postrema Increases Food Intake in Rats","volume":"81","author":"Mollet","year":"2004","journal-title":"Physiol. Behav."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/osp4.62","article-title":"Amylin\/Leptin Synergy Is Absent in Extreme Obesity and Not Restored by Calorie Restriction-induced Weight Loss in Rats","volume":"2","author":"Trevaskis","year":"2016","journal-title":"Obes. Sci. Pract."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000084488","article-title":"Chronically Administered Islet Amyloid Polypeptide in Rats Serves as an Adiposity Inhibitor and Regulates Energy Homeostasis","volume":"5","author":"Isaksson","year":"2005","journal-title":"Pancreatology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.physbeh.2010.04.012","article-title":"Central Amylin Acts as an Adiposity Signal to Control Body Weight and Energy Expenditure","volume":"101","author":"Wielinga","year":"2010","journal-title":"Physiol. Behav."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"944","DOI":"10.2174\/1389203720666190328111833","article-title":"Human Amylin: From Pathology to Physiology and Pharmacology","volume":"20","author":"Ling","year":"2019","journal-title":"Curr. Protein Pept. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e199826","DOI":"10.1001\/jamanetworkopen.2019.9826","article-title":"Association of Plasma Amylin Concentration With Alzheimer Disease and Brain Structure in Older Adults","volume":"2","author":"Zhu","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.parkreldis.2020.08.018","article-title":"Peripheral Insulin and Amylin Levels in Parkinson\u2019s Disease","volume":"79","author":"Ezquerra","year":"2020","journal-title":"Park. Relat. Disord."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.parkreldis.2020.10.013","article-title":"Insulin Resistance, Diabetes and Parkinson\u2019s Disease: The Match Continues","volume":"80","author":"Delamarre","year":"2020","journal-title":"Park. Relat. Disord."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"47S","DOI":"10.1177\/0145721715607642","article-title":"Role of Amylin in Type 1 and Type 2 Diabetes","volume":"41","author":"Hieronymus","year":"2015","journal-title":"Diabetes Educ."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.2337\/diab.40.12.1615","article-title":"Decrease of Stimulated Amylin Release Precedes Impairment of Insulin Secretion in Type II Diabetes","volume":"40","author":"Ludvik","year":"1991","journal-title":"Diabetes"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0168-8227(92)90074-2","article-title":"Plasma Islet Amyloid Polypeptide Levels in Obesity, Impaired Glucose Tolerance and Non-Insulin-Dependent Diabetes Mellitus","volume":"15","author":"Enoki","year":"1992","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1210\/endo.138.8.5312","article-title":"Characterization of Amylin and Calcitonin Receptor Binding in the Mouse \u03b1-Thyroid-Stimulating Hormone Thyrotroph Cell Line*","volume":"138","author":"Perry","year":"1997","journal-title":"Endocrinology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1124\/mol.56.1.235","article-title":"Multiple Amylin Receptors Arise from Receptor Activity-Modifying Protein Interaction with the Calcitonin Receptor Gene Product","volume":"56","author":"Christopoulos","year":"1999","journal-title":"Mol. Pharmacol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1210\/endo.140.6.6930","article-title":"An Amylin Receptor Is Revealed Following Co-Transfection of a Calcitonin Receptor with Receptor Activity Modifying Proteins-1 or -3","volume":"140","author":"Muff","year":"1999","journal-title":"Endocrinology"},{"key":"ref_44","first-page":"61","article-title":"Amylin Receptor Phenotypes Derived from Human Calcitonin Receptor\/RAMP Coexpression Exhibit Pharmacological Differences Dependent on Receptor Isoform and Host Cell Environment","volume":"294","author":"Tilakaratne","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1172\/JCI116046","article-title":"Cloning, Characterization, and Expression of a Human Calcitonin Receptor from an Ovarian Carcinoma Cell Line","volume":"90","author":"Gorn","year":"1992","journal-title":"J. Clin. Investig."},{"key":"ref_46","first-page":"246","article-title":"Cloning and Characterization of an Abundant Subtype of the Human Calcitonin Receptor","volume":"46","author":"Kuestner","year":"1994","journal-title":"Mol. Pharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/30666","article-title":"RAMPs Regulate the Transport and Ligand Specificity of the Calcitonin-Receptor-like Receptor","volume":"393","author":"McLatchie","year":"1998","journal-title":"Nature"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1210\/endo.140.6.6930","article-title":"A Receptor Activity Modifying Protein (RAMP)2-Dependent Adrenomedullin Receptor Is a Calcitonin Gene-Related Peptide Receptor When Coexpressed with Human RAMP1","volume":"140","author":"Muff","year":"1999","journal-title":"Endocrinology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1124\/mol.55.6.1054","article-title":"The Amino Terminus of Receptor Activity Modifying Proteins Is a Critical Determinant of Glycosylation State and Ligand Binding of Calcitonin Receptor-like Receptor","volume":"55","author":"Fraser","year":"1999","journal-title":"Mol. Pharmacol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Hay, D.L., and Dickerson, I.M. (2010). The Calcitonin Gene-related Peptide Family, Springer.","DOI":"10.1007\/978-90-481-2909-6"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1586\/14789450.2013.841549","article-title":"Amylin: What Might Be Its Role in Alzheimer\u2019s Disease and How Could This Affect Therapy?","volume":"10","author":"Despa","year":"2013","journal-title":"Expert Rev. Proteom."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.molmet.2017.11.009","article-title":"Amylin\u2014Its Role in the Homeostatic and Hedonic Control of Eating and Recent Developments of Amylin Analogs to Treat Obesity","volume":"8","author":"Boyle","year":"2017","journal-title":"Mol. Metab."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3389\/fnagi.2013.00042","article-title":"Amylin Receptor: A Common Pathophysiological Target in Alzheimer\u2019s Disease and Diabetes Mellitus","volume":"5","author":"Fu","year":"2013","journal-title":"Front. Aging Neurosci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"10942","DOI":"10.1038\/s41598-019-47255-9","article-title":"Short Amylin Receptor Antagonist Peptides Improve Memory Deficits in Alzheimer\u2019s Disease Mouse Model","volume":"9","author":"Soudy","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1038\/npp.2013.66","article-title":"Amylin Receptor Signaling in the Ventral Tegmental Area Is Physiologically Relevant for the Control of Food Intake","volume":"38","author":"Rupprecht","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/acn3.197","article-title":"A Second Trigeminal CGRP Receptor: Function and Expression of the AMY1 Receptor","volume":"2","author":"Walker","year":"2015","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2147\/VHRM.S1978","article-title":"Pramlintide, the Synthetic Analogue of Amylin: Physiology, Pathophysiology, and Effects on Glycemic Control, Body Weight, and Selected Biomarkers of Vascular Risk","volume":"4","author":"Hoogwerf","year":"2008","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.2146\/ajhp050341","article-title":"Pramlintide Acetate","volume":"62","author":"McQueen","year":"2005","journal-title":"Am. J. Health-Syst. Pharm."},{"key":"ref_59","unstructured":"Katzung, B.G. (2018). Basic & Clinical Pharmacology, McGraw-Hill Education. [14th ed.]."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"155332","DOI":"10.1016\/j.metabol.2022.155332","article-title":"Pharmacotherapy of Type 2 Diabetes: An Update and Future Directions","volume":"137","author":"DeMarsilis","year":"2022","journal-title":"Metabolism"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1089\/15209150252924094","article-title":"Adjunctive Therapy with the Amylin Analogue Pramlintide Leads to a Combined Improvement in Glycemic and Weight Control in Insulin-Treated Subjects with Type 2 Diabetes","volume":"4","author":"Ratner","year":"2002","journal-title":"Diabetes Technol. Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"784","DOI":"10.2337\/diacare.26.3.784","article-title":"Pramlintide as an Adjunct to Insulin Therapy Improves Long-Term Glycemic and Weight Control in Patients with Type 2 Diabetes","volume":"26","author":"Hollander","year":"2003","journal-title":"Diabetes Care"},{"key":"ref_64","unstructured":"(2023, December 28). SYMLIN\u00ae (Pramlintide Acetate) Injection, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/021332s006lbl.pdf."},{"key":"ref_65","unstructured":"(2023, December 28). Drug Approval Package: Symlin (Pramlintide Acetate) NDA #021332, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2005\/21-332_Symlin.cfm."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1089\/dia.2006.0013","article-title":"Pramlintide as An Adjunct to Insulin in Patients with Type 2 Diabetes in A Clinical Practice Setting Reduced A1C, Postprandial Glucose Excursions, And Weight","volume":"9","author":"Karl","year":"2007","journal-title":"Diabetes Technol. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/j.1463-1326.2010.01201.x","article-title":"Safety of Pramlintide Added to Mealtime Insulin in Patients with Type 1 or Type 2 Diabetes: A Large Observational Study","volume":"12","author":"Pencek","year":"2010","journal-title":"Diabetes Obes. Metab."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.2337\/dc07-0589","article-title":"Pramlintide Improved Glycemic Control and Reduced Weight in Patients with Type 2 Diabetes Using Basal Insulin","volume":"30","author":"Riddle","year":"2007","journal-title":"Diabetes Care"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1185\/03007991003634759","article-title":"Patient Reported Outcomes in Adults with Type 2 Diabetes on Basal Insulin Randomized to Addition of Mealtime Pramlintide or Rapid-Acting Insulin Analogs","volume":"26","author":"Peyrot","year":"2010","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"724","DOI":"10.2337\/diacare.25.4.724","article-title":"A Randomized Study and Open-Label Extension Evaluating the Long-Term Efficacy of Pramlintide as an Adjunct to Insulin Therapy in Type 1 Diabetes","volume":"25","author":"Whitehouse","year":"2002","journal-title":"Diabetes Care"},{"key":"ref_71","first-page":"A232","article-title":"Pramlintide Therapy in Addition to Insulin in Type 2 Diabetes: Effect on Metabolic Control after 6 Months","volume":"42","author":"Gottlieb","year":"1999","journal-title":"Diabetologia"},{"key":"ref_72","first-page":"23","article-title":"Pramlintide, an Antidiabetic, Is Antineoplastic in Colorectal Cancer and Synergizes with Conventional Chemotherapy","volume":"10","author":"Alsmadi","year":"2018","journal-title":"Clin. Pharmacol. Adv. Appl."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nature13910","article-title":"IAPP-Driven Metabolic Reprogramming Induces Regression of P53-Deficient Tumours in Vivo","volume":"517","author":"Venkatanarayan","year":"2015","journal-title":"Nature"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Yang, Y., Peng, Z., Flores, E.R., and Kleinerman, E.S. (2022). Pramlintide: A Novel Therapeutic Approach for Osteosarcoma through Metabolic Reprogramming. Cancers, 14.","DOI":"10.3390\/cancers14174310"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40842-016-0030-z","article-title":"Cardiovascular Safety Assessment of Pramlintide in Type 2 Diabetes: Results from a Pooled Analysis of Five Clinical Trials","volume":"2","author":"Herrmann","year":"2016","journal-title":"Clin. Diabetes Endocrinol."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"ORIGIN Trial Investigators, Gerstein, H.C., Bosch, J., Dagenais, G.R., D\u00edaz, R., Jung, H., Maggioni, A.P., Pogue, J., Probstfield, J., and Ramachandran, A. (2012). Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia. N. Engl. J. Med., 367, 319\u2013328.","DOI":"10.1056\/NEJMoa1203858"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.2337\/dc06-0042","article-title":"A Double-Blind, Placebo-Controlled Trial Assessing Pramlintide Treatment in the Setting of Intensive Insulin Therapy in Type 1 Diabetes","volume":"29","author":"Edelman","year":"2006","journal-title":"Diabetes Care"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/j.1464-5491.2004.01319.x","article-title":"Amylin Replacement with Pramlintide as an Adjunct to Insulin Therapy Improves Long-term Glycaemic and Weight Control in Type 1 Diabetes Mellitus: A 1-year, Randomized Controlled Trial","volume":"21","author":"Ratner","year":"2004","journal-title":"Diabet. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.2337\/dc12-0330","article-title":"Effect of Pramlintide on Prandial Glycemic Excursions during Closed-Loop Control in Adolescents and Young Adults with Type 1 Diabetes","volume":"35","author":"Weinzimer","year":"2012","journal-title":"Diabetes Care"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/dom.14302","article-title":"ADO09, a Co-formulation of the Amylin Analogue Pramlintide and the Insulin Analogue A21G, Lowers Postprandial Blood Glucose versus Insulin Lispro in Type 1 Diabetes","volume":"23","author":"Andersen","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Larsen, A.T., Mohamed, K.E., Sonne, N., Bredtoft, E., Andersen, F., Karsdal, M., and Henriksen, K. (2022). Does Receptor Balance Matter?\u2014Comparing the Efficacies of the Dual Amylin and Calcitonin Receptor Agonists Cagrilintide and KBP-336 on Metabolic Parameters in Preclinical Models. Biomed. Pharmacother., 156.","DOI":"10.1016\/j.biopha.2022.113842"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"170939","DOI":"10.1016\/j.peptides.2023.170939","article-title":"An Update on Peptide-Based Therapies for Type 2 Diabetes and Obesity","volume":"161","author":"Bailey","year":"2023","journal-title":"Peptides"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S0140-6736(23)01163-7","article-title":"Efficacy and Safety of Co-Administered Once-Weekly Cagrilintide 2\u00b74 Mg with Once-Weekly Semaglutide 2\u00b74 Mg in Type 2 Diabetes: A Multicentre, Randomised, Double-Blind, Active-Controlled, Phase 2 Trial","volume":"402","author":"Frias","year":"2023","journal-title":"Lancet"},{"key":"ref_84","unstructured":"Novo Nordisk A\/S (2024, January 18). Efficacy and Safety of Co-Administered Cagrilintide and Semaglutide (CagriSema) s.c. in Doses 2.4\/2.4 Mg and 1.0\/1.0 Mg Once Weekly versus Semaglutide 2.4 Mg and 1.0 Mg, Cagrilintide 2.4 Mg and Placebo in Participants with Type 2 Diabetes Inadequately Controlled on Metformin with or without an SGLT2 Inhibitor, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT06065540."},{"key":"ref_85","unstructured":"Novo Nordisk A\/S (2024, January 18). Efficacy and Safety of Cagrilintide s.c. 2.4 Mg in Combination with Semaglutide s.c. 2.4 Mg (CagriSema s.c. 2.4 Mg\/2.4 Mg) Once-Weekly in Participants with Overweight or Obesity and Type 2 Diabetes, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05394519?term=NCT05394519&rank=1."},{"key":"ref_86","unstructured":"Novo Nordisk A\/S (2024, January 18). Efficacy and Safety of Co-Administered Cagrilintide and Semaglutide (CagriSema 2.4 Mg\/2.4 Mg) Once Weekly versus Semaglutide 2.4 Mg, Cagrilintide 2.4 Mg and Placebo in People with Chronic Kidney Disease and Type 2 Diabetes Living with Overweight or Obesity, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06131372?term=NCT06131372&rank=1."},{"key":"ref_87","unstructured":"Novo Nordisk A\/S (2023, January 18). Efficacy and Safety of Cagrilintide s.c. 2.4 Milligram (Mg) in Combination with Semaglutide Subcutaneous (s.c). 2.4 Mg (CagriSema s.c. 2.4 Mg\/2.4 Mg) Once-Weekly in Participants with Overweight or Obesity, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05567796?term=NCT05567796&rank=1."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/S0140-6736(21)01751-7","article-title":"Once-Weekly Cagrilintide for Weight Management in People with Overweight and Obesity: A Multicentre, Randomised, Double-Blind, Placebo-Controlled and Active-Controlled, Dose-Finding Phase 2 Trial","volume":"398","author":"Lau","year":"2021","journal-title":"Lancet"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(21)00845-X","article-title":"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Concomitant Administration of Multiple Doses of Cagrilintide with Semaglutide 2\u00b74 Mg for Weight Management: A Randomised, Controlled, Phase 1b Trial","volume":"397","author":"Enebo","year":"2021","journal-title":"Lancet"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/3\/1517\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:49:36Z","timestamp":1760104176000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/3\/1517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,26]]},"references-count":89,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["ijms25031517"],"URL":"https:\/\/doi.org\/10.3390\/ijms25031517","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,26]]}}}